Financial PerformanceThe company reported an EPS of ($0.57), which was lower than both analyst expectations of ($0.51) and the broader market consensus of ($0.47), primarily due to increased compensation and headcount expenses.
Reimbursement ChangesThere is a possibility that CMS may reassign CVRx's Barostim to a lower reimbursement code, potentially reducing its reimbursement amount from $45K to approximately $31.2K, which could negatively impact financial performance.
Revenue ForecastManagement has lowered the company's 2025 revenue estimates, signaling potential challenges in achieving previous growth projections.